Table 3 Bevacizumab biosimilars in late-stage clinical development
From: Will bevacizumab biosimilars impact the value of systemic therapy in gynecologic cancers?
Sponsor | Biosimilar candidate | Patient population | Study objectives | Key findings |
|---|---|---|---|---|
Amgen | ABP 215 | NSCLC | Functional similarity and PK equivalence | •Similar functional characteristics •Equivalent PK [26] |
NSCLC | Clinical equivalence of objective response rate | •Clinical equivalence •Similar safety and immunogenic profiles to bevacizumab [20] | ||
Biocad | BCD-021 | NSCLC | PK and safety | •Similar PK and safety [21] |
NSCLC | Overall response rate | •Similar efficacy, safety and immunogenicity [22] | ||
Boehringer Ingelheim | BI 695502 | NSCLC | Efficacy and safety | •Recruiting (NCT02272413) |
mCRC | Efficacy and safety | •Recruiting (NCT02776683) | ||
Pfizer | PF-06439535 | NSCLC | Nonclinical evaluation | •Similar structure and in vitro biological activity [24] •Similar in vivo toxicology [24] |
NSCLC | PK and safety | •PK similarity [25] •Comparable safety profile [25] | ||
NSCLC | Comparative efficacy and safety | •Ongoing (NCT02364999) |